ATE216402T1 - Opioid-konjugate mit endogenen trägerproteinen - Google Patents
Opioid-konjugate mit endogenen trägerproteinenInfo
- Publication number
- ATE216402T1 ATE216402T1 AT98956656T AT98956656T ATE216402T1 AT E216402 T1 ATE216402 T1 AT E216402T1 AT 98956656 T AT98956656 T AT 98956656T AT 98956656 T AT98956656 T AT 98956656T AT E216402 T1 ATE216402 T1 AT E216402T1
- Authority
- AT
- Austria
- Prior art keywords
- patient
- conjugates
- antinociceptive
- conjugate
- vivo
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108010078791 Carrier Proteins Proteins 0.000 title 1
- 239000003965 antinociceptive agent Substances 0.000 abstract 3
- 230000002792 vascular Effects 0.000 abstract 2
- 108010065372 Dynorphins Proteins 0.000 abstract 1
- 108010049140 Endorphins Proteins 0.000 abstract 1
- 102000009025 Endorphins Human genes 0.000 abstract 1
- 108010092674 Enkephalins Proteins 0.000 abstract 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 239000012503 blood component Substances 0.000 abstract 1
- -1 deltorphins Proteins 0.000 abstract 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000004081 narcotic agent Substances 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6470597P | 1997-11-07 | 1997-11-07 | |
| PCT/US1998/023704 WO1999024074A2 (en) | 1997-11-07 | 1998-11-06 | Novel conjugates of opioids and endogenous carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE216402T1 true ATE216402T1 (de) | 2002-05-15 |
Family
ID=22057753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98956656T ATE216402T1 (de) | 1997-11-07 | 1998-11-06 | Opioid-konjugate mit endogenen trägerproteinen |
| AT01121557T ATE235513T1 (de) | 1997-11-07 | 1998-11-06 | Opioid-konjugate mit endogenen trägerproteinen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01121557T ATE235513T1 (de) | 1997-11-07 | 1998-11-06 | Opioid-konjugate mit endogenen trägerproteinen |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1007561B1 (de) |
| JP (2) | JP2001522863A (de) |
| AT (2) | ATE216402T1 (de) |
| AU (3) | AU750387B2 (de) |
| CA (2) | CA2301799C (de) |
| DE (2) | DE69804974T2 (de) |
| ES (1) | ES2173641T3 (de) |
| IL (1) | IL135835A0 (de) |
| WO (3) | WO1999024074A2 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437092B1 (en) | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
| CA2291066A1 (en) * | 1998-03-23 | 1999-09-30 | Conjuchem, Inc. | Local delivery of long lasting therapeutic agents |
| HK1042114B (zh) | 1998-10-23 | 2006-09-29 | Amgen K-A, Inc. | 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽 |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| EP1623994A3 (de) * | 1999-05-17 | 2008-07-16 | ConjuChem Biotechnologies Inc. | Schutz endogener therapeutisch aktiver Peptide vor Peptidaseaktivität durch Konjugation an Blutbestandteile |
| JP4209086B2 (ja) * | 1999-05-17 | 2009-01-14 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 長期持続性抗新脈管形成ペプチド |
| US7144854B1 (en) | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
| BR0010757A (pt) | 1999-05-17 | 2002-02-19 | Conjuchem Inc | Inibidores de peptìdeo de fusão de longa duração de infecção viral |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| SI1180121T1 (en) * | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
| US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
| CN1491233A (zh) | 2001-02-02 | 2004-04-21 | 康久化学公司 | 长效生长激素释放因子衍生物 |
| ATE396202T1 (de) | 2001-02-16 | 2008-06-15 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| DK1479691T3 (da) | 2001-05-31 | 2007-03-12 | John Erickson | Langvarigt aktive fuionspeptidinhibitorer for HIV infektion |
| WO2004066917A2 (en) | 2003-01-17 | 2004-08-12 | Advanced Proteome Therapeutics, Inc | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites |
| CA2564031A1 (en) | 2004-04-23 | 2005-11-03 | Conjuchem Biotechnologies Inc. | Method for the purification of albumin conjugates |
| CA2572765C (en) | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
| US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| US7982018B2 (en) | 2006-10-16 | 2011-07-19 | Conjuchem, Llc | Modified corticotropin releasing factor peptides and uses thereof |
| GB201204868D0 (en) | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
| US20170158599A1 (en) * | 2014-07-18 | 2017-06-08 | Joseph D. Ceccoli | Compositions and methods comprising salicylates and polysalicylates |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59138958A (ja) * | 1983-01-31 | 1984-08-09 | Mitsubishi Chem Ind Ltd | 抗血清 |
| US4784955A (en) * | 1984-09-21 | 1988-11-15 | Miles Inc. | Immunogen conjugates and the use thereof in a dihydropyridine assay |
| IE901736L (en) * | 1989-05-17 | 1990-11-17 | Fuller H B Licensing Financ | Polypeptide-antibody conjugate for inhibiting cell adhesion |
| DK608589D0 (da) * | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
| US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
| JPH04364200A (ja) * | 1991-06-10 | 1992-12-16 | Unitika Ltd | 細胞接着性アルブミン |
| US5399671A (en) * | 1992-11-18 | 1995-03-21 | Kluger; Ronald | Specifically crosslinked hemoglobin with free functionality |
| US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
-
1998
- 1998-11-06 JP JP2000520470A patent/JP2001522863A/ja active Pending
- 1998-11-06 WO PCT/US1998/023704 patent/WO1999024074A2/en not_active Ceased
- 1998-11-06 AT AT98956656T patent/ATE216402T1/de not_active IP Right Cessation
- 1998-11-06 AT AT01121557T patent/ATE235513T1/de not_active IP Right Cessation
- 1998-11-06 EP EP98956656A patent/EP1007561B1/de not_active Expired - Lifetime
- 1998-11-06 CA CA002301799A patent/CA2301799C/en not_active Expired - Fee Related
- 1998-11-06 EP EP98957648A patent/EP1028971A2/de not_active Withdrawn
- 1998-11-06 CA CA002309205A patent/CA2309205A1/en not_active Abandoned
- 1998-11-06 WO PCT/US1998/023702 patent/WO1999024462A2/en not_active Ceased
- 1998-11-06 AU AU13127/99A patent/AU750387B2/en not_active Ceased
- 1998-11-06 WO PCT/US1998/023706 patent/WO1999024076A2/en not_active Ceased
- 1998-11-06 AU AU13856/99A patent/AU1385699A/en not_active Abandoned
- 1998-11-06 DE DE69804974T patent/DE69804974T2/de not_active Expired - Lifetime
- 1998-11-06 DE DE69812727T patent/DE69812727D1/de not_active Expired - Lifetime
- 1998-11-06 IL IL13583598A patent/IL135835A0/xx unknown
- 1998-11-06 ES ES98956656T patent/ES2173641T3/es not_active Expired - Lifetime
- 1998-11-06 JP JP2000520159A patent/JP2001522817A/ja active Pending
- 1998-11-06 AU AU15197/99A patent/AU1519799A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU750387B2 (en) | 2002-07-18 |
| DE69812727D1 (de) | 2003-04-30 |
| EP1007561A2 (de) | 2000-06-14 |
| EP1007561B1 (de) | 2002-04-17 |
| WO1999024074A2 (en) | 1999-05-20 |
| WO1999024076A9 (en) | 2000-06-08 |
| DE69804974T2 (de) | 2002-11-07 |
| EP1028971A2 (de) | 2000-08-23 |
| WO1999024076A3 (en) | 1999-08-19 |
| ATE235513T1 (de) | 2003-04-15 |
| WO1999024462A2 (en) | 1999-05-20 |
| CA2309205A1 (en) | 1999-05-20 |
| ES2173641T3 (es) | 2002-10-16 |
| AU1385699A (en) | 1999-05-31 |
| CA2301799C (en) | 2007-08-07 |
| CA2301799A1 (en) | 1999-05-20 |
| AU1519799A (en) | 1999-05-31 |
| WO1999024076A2 (en) | 1999-05-20 |
| AU1312799A (en) | 1999-05-31 |
| IL135835A0 (en) | 2001-05-20 |
| JP2001522817A (ja) | 2001-11-20 |
| WO1999024074A3 (en) | 1999-08-19 |
| DE69804974D1 (de) | 2002-05-23 |
| WO1999024462A3 (en) | 1999-08-26 |
| JP2001522863A (ja) | 2001-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE235513T1 (de) | Opioid-konjugate mit endogenen trägerproteinen | |
| Ringsdorf | Structure and properties of pharmacologically active polymers | |
| CA2064689A1 (en) | Stabilized protein or peptide conjugates | |
| ATE142506T1 (de) | Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin- technologie | |
| NO20015584D0 (no) | Lantidsvarende insulintrofiske peptider | |
| WO1988000834A1 (en) | Chimeric peptides for neuropeptide delivery through the blood-brain barrier | |
| WO1999048536A3 (en) | Delivery of long lasting therapeutic agents by forming covalent attachments in vivo | |
| Poznansky et al. | Insulin: carrier potential for enzyme and drug therapy | |
| WO1999056723A3 (en) | Hemoglobine-haptoglobin complexes for targeted drug delivery | |
| WO2001060412A3 (en) | Modification of biopolymers for improved drug delivery | |
| IL161670A0 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| US5411943A (en) | Hepatoma treatment with somatostatin analogs | |
| Habberfield et al. | Vitamin B12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo | |
| AU2002238687B2 (en) | Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same | |
| AU2503900A (en) | Sulfated phosphatidylinositols, their preparation and use | |
| Basu et al. | Enhanced intracellular delivery of doxorubicin by scavenger receptor‐mediated endocytosis for preferential killing of histiocytic lymphoma cells in culture | |
| IL117564A0 (en) | Pharmaceutical and diagnostic compositions containing lysine derivatives | |
| TH55748A (th) | การใช้อินเทอร์เฟรอน-เบต้าในการบำบัดรักษาของเนื้องอกประเภทของอีวิง | |
| Wheeler | RG-1068 RepliGen | |
| Squibb | INTROS | |
| ITMI960133A1 (it) | Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili | |
| MD1135F1 (en) | Paradontium treatment method | |
| CA2326720A1 (en) | Hemoglobin-haptoglobin complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |